The SARS-CoV-2 pandemic and worldwide anti-epidemic measures have impacted both the lives of people and the functioning of businesses. Coronavirus spread was also promptly responded by organizations coordinating the biobanking of cord blood, other human cells and tissues, and hematopoietic stem cell donor registries, making a number of important recommendations to cryobanks and appropriate corrections to the existing conditions.
Therefore, the Food and Drug Administration (FDA) in the United States has released important information for biobanks and manufacturers of preparations containing human cells or tissues, although there is no evidence that respiratory viruses to which COVID-19 belongs may be transmitted through cell or tissue preparations, biomaterial donor screening programs may require the following information:
- whether they traveled to the regions with COVID-19 cases;
- whether they lived with persons infected with COVID-19 or who were suspected coronavirus;
- whether were infected with COVID-19 or whether a coronavirus was suspected.
The World Marrow Donor Association (WMDA) has reported that the use of umbilical cord blood during pandemics is now particularly relevant as frozen cord blood samples are ready for use, and anti-epidemic conditions may not allow testing of the bone marrow donors or the processing of their biomaterial.